July 08, 2025 a 08:00 am
LLY: Fundamental Ratio Analysis - Eli Lilly and Company
Eli Lilly and Company (LLY) is one of the leading pharmaceutical companies with a strong focus on innovative drugs for a variety of medical conditions. The company's robust product pipeline and established market presence provide opportunities for sustained growth. However, like others in the sector, it faces challenges such as regulatory pressures and competitive market dynamics.
Fundamental Rating
The current fundamental rating of Eli Lilly shows a promising outlook with strengths across key financial metrics.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
Over the past period, Eli Lilly's ratings show a consistent trend, reflecting stability in its financial fundamentals.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-07 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| Previous | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
Analyst Target Prices
Analysts present a bullish outlook with high expected price targets, showcasing confidence in Eli Lilly's future performance.
| High | Low | Median | Consensus |
|---|---|---|---|
| $1,146 | $700 | $970 | $963.2 |
Analyst Sentiment
The consensus among analysts indicates strong optimism with a majority of buy recommendations.
| Recommendation | Number | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 7 | |
| Sell | 3 | |
| Strong Sell | 0 |
Conclusion
Eli Lilly and Company presents a strong investment opportunity with robust fundamentals and promising analyst endorsements. The pharmaceutical giant's diverse product lineup and strategic partnerships underline its growth potential. Nevertheless, potential investors should be aware of external pressures like regulatory changes and sector competition. Overall, the company's solid track record and market leadership position it well for future growth.